Teva Pharmaceuticals has announced that the Medicines Management Programme (MMP) now recommends Lonquex (lipegfilgrastim) as a Best-Value Biological (BVB) Medicine for the long-acting granulocyte-colony stimulating factors on the High Tech Arrangement. Lonquex is indicated in adults for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndrome).   Further information is available upon request, see teva.ie for contact details, or from the SmPC available at HPRA.ie. Product information is also available on the HPRA website.